ArticleCase reports in oncological medicine2025
Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank.
Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Classical Hodgkin lymphoma (cHL) is a highly curable B-cell malignancy; though, rarely, it can transform into non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, or marginal zone lymphoma. Reports of such transformations remain limited in the literature. Objective: The aim of this study is to describe the clinical course, histopathological findings, and outcomes of three patients with cHL who developed secondary NHL. Results: Case 1 involved transformation from cHL to CD20+/CD30+ DLBCL following multiple lines of chemotherapy and autologous stem cell transplant, eventually resulting in progressive disease and death. Case 2 transformed into follicular lymphoma Grade 3a more than a year after cHL remission, with marrow infiltration managed conservatively pending systemic therapy. Case 3 presented with composite lymphoma at diagnosis (cHL and extranodal marginal zone lymphoma) and experienced indolent but recurrent disease involving the liver, requiring multiple rounds of chemoimmunotherapy. Conclusion: Transformation of cHL into NHL, though rare, may occur years after initial treatment or concurrently at presentation. These cases underscore the importance of repeat biopsy in suspected relapses and highlight the clinical and pathological heterogeneity of such transformations. Our paper adds to the limited literature on this phenomenon and is the first of its kind reported from Palestine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.